Monoclonal antibody · Inhibitor of complement component C5 (C5) · developed by Alexion Pharm
Ravulizumab is an antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage into C5a and C5b and thereby preventing membrane attack complex formation. It is used in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder and IgA nephropathy. It is also being studied in myasthenia gravis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 29, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06909253 | N/A | Myasthenia Gravis, Generalized | Recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myasthenia Gravis, Generalized
Updated Nov 22, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →